TY - JOUR
T1 - Caregiver burden in alzheimer disease
T2 - Cross-sectional and longitudinal patient correlates
AU - Mohamed, Somaia
AU - Rosenheck, Robert
AU - Lyketsos, Constantine G.
AU - Schneider, Lon S.
N1 - Funding Information:
This work was supported by grant NO1 MH9001 from NIMH and by Wyeth Pharmaceuticals .
Funding Information:
Robert Rosenheck has received research support from Eli Lilly, Janssen Pharmaceutica, Astra-Zeneca, and Wyeth Pharmaceuticals. He has been a consultant to GlaxoSmithKline, Bristol Myers Squibb, Organon, and Janssen Pharmaceutica. He provided expert testimony for the plaintiffs in UFCW Local 1776 and Participating Employers Health and Welfare Fund, et al. v. Eli Lilly and Company; for the respondent in Eli Lilly Canada Inc. versus Novapharm Ltd. and Minister of Health, respondent; and for the Patent Medicines Prices Review Board, Canada, in the matter of Janssen Ortho Inc. and “Risperdal Consta.” Lon Schneider has received research funding from Pfizer, Inc. He has been a consultant to AstraZeneca, Bristol Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Johnson and Johnson, and Wyeth and provided testimony, reports, or consultation in cases involving AstraZeneca, Eli Lilly, Johnson and Johnson.
PY - 2010/10
Y1 - 2010/10
N2 - Objectives: Alzheimer disease (AD) imposes a severe burden on patients and their caregivers. Although there is substantial evidence of the adverse impact of burden, considerably less is known about its specific correlates and potential causes. Design: The authors use data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-AD study to examine the relationship of burden and depression among AD caregivers to patient and caregiver sociodemographic characteristics, patients' cognitive status, psychiatric and behavioral symptoms, functional abilities, quality of life, and intensity of care provided by caregivers. Setting: CATIE-AD included outpatients in usual care settings and assessed treatment outcomes during 9 months. Participants: Data were examined from 421 ambulatory outpatients with a diagnosis of dementia of the Alzheimer type or probable AD with agitation or psychosis. Measures: The Burden Interview, the Beck Depression Inventory, and the Caregiver Distress Scale were used to evaluate caregiver burden. Results: More severe psychiatric and behavioral problems and decreased patient quality of life, as well as lower functional capability were significantly associated with higher levels of burden and depression among caregivers at baseline. Six-month changes showed that decreased symptoms and improved quality of life were associated with decreased burden and accounted for most of the explained variance in change in burden measures. Conclusion: Severity of psychiatric symptoms, behavioral disturbances, and patients' quality of life are the main correlates of caregivers' experience burden. Psychosocial and pharmacologic interventions targeting these two aspects of the disorder are likely to not only alleviate patient suffering but also promote caregiver well-being.
AB - Objectives: Alzheimer disease (AD) imposes a severe burden on patients and their caregivers. Although there is substantial evidence of the adverse impact of burden, considerably less is known about its specific correlates and potential causes. Design: The authors use data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-AD study to examine the relationship of burden and depression among AD caregivers to patient and caregiver sociodemographic characteristics, patients' cognitive status, psychiatric and behavioral symptoms, functional abilities, quality of life, and intensity of care provided by caregivers. Setting: CATIE-AD included outpatients in usual care settings and assessed treatment outcomes during 9 months. Participants: Data were examined from 421 ambulatory outpatients with a diagnosis of dementia of the Alzheimer type or probable AD with agitation or psychosis. Measures: The Burden Interview, the Beck Depression Inventory, and the Caregiver Distress Scale were used to evaluate caregiver burden. Results: More severe psychiatric and behavioral problems and decreased patient quality of life, as well as lower functional capability were significantly associated with higher levels of burden and depression among caregivers at baseline. Six-month changes showed that decreased symptoms and improved quality of life were associated with decreased burden and accounted for most of the explained variance in change in burden measures. Conclusion: Severity of psychiatric symptoms, behavioral disturbances, and patients' quality of life are the main correlates of caregivers' experience burden. Psychosocial and pharmacologic interventions targeting these two aspects of the disorder are likely to not only alleviate patient suffering but also promote caregiver well-being.
KW - Alzheimer disease
KW - Caregivers burden
KW - antipsychotics
UR - http://www.scopus.com/inward/record.url?scp=77958062562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958062562&partnerID=8YFLogxK
U2 - 10.1097/JGP.0b013e3181d5745d
DO - 10.1097/JGP.0b013e3181d5745d
M3 - Article
C2 - 20808108
AN - SCOPUS:77958062562
SN - 1064-7481
VL - 18
SP - 917
EP - 927
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 10
ER -